


**Product Name** : AMXI-5001  
**Cat. No.** : PC-72149  
**CAS No.** : 2170491-77-5  
**Molecular Formula** : C<sub>25</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 457.465  
**Target** : PARP  
**Solubility** : 10 mM in DMSO



## Biological Activity

AMXI-5001 (AMXI 5001) is a novel, highly potent, orally active dual **PARP1/2** (IC<sub>50</sub> 5/0.05 nM) and microtubule polymerization inhibitor, inhibits intracellular PAR formation with IC<sub>50</sub> of 7 nM.

AMXI-5001 binds to the catalytic domain of human PARP1 and is a weak tankyrase inhibitor (800-fold lower than IC<sub>50</sub> towards either PARP1 or PARP2 enzymes).

AMXI-5001 inhibited tubulin polymerization in a dose-dependent manner.

AMXI-5001 exhibited selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC<sub>50</sub>s than existing clinical PARP1/2 inhibitors.

AMXI-5001 is highly active in both BRCA mutated and wild type cancers.

AMXI-5001 elicited a remarkable *In vivo* preclinical anti-tumor activity in a BRCA mutated TNBC model induced complete regression of established tumors, including exceedingly large tumors, demonstrated superior anti-tumor effects compared to either single agent (PARP or microtubule) inhibitor or combination with both agents.

## References

Hassan Lemjabbar-Alaoui, et al. *Am J Cancer Res.* 2020 Aug 1;10(8):2649-2676.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com